home mri radiation employment healthcareprofessional aboutthecenter
patientsguide rotour rotechnology rostaff rolinks romaps rocontact
         

ABOUT Prostate Cancer

The following information is provided for a better understanding of the disease and does not replace the dialogue men should have with their physician regarding screening and treatment for prostate cancer.

In The News

A complex and usually slow growing cancer, prostate cancer is the most common non-skin cancer and the second leading cause of cancer death in the US today. However, because of potential harms in treatment of prostate cancer that would never have developed symptoms related to cancer in their lifetime, screening guidelines for men have changed. One physician writing for the American Cancer Society writes” …the sad reality that there is much we don’t know about the diagnosis and treatment of this very common cancer.” We do know that most prostate cancers grow very slowly, and because of this other medical illness will cause the affected man’s death. Adding to the confusion, there are some prostate cancers that are more aggressive. Because of these factors the following guidelines are now recommended:

Most physicians offer prostate screening to men aged 50. Physicians should still make the same recommendation to their patients as they have for several years: be informed and make a choice on what you want to do. For African-American men, who are at a higher risk of death from prostate cancer than white men, the American Cancer Society recommends the test should be done beginning at age 45. That is not the same as offering the test. The same is true for any man with a first degree relative who has had prostate cancer. And for men with more than one first degree relative with prostate cancer, they can consider testing beginning at age 40.

The Annals of Internal Medicine, established by the American College of Physicians is now recommending men 75 and older not be screened for prostate cancer as “there is moderate certainty that the harms of screening for prostate cancer outweigh the benefits.”*

In other news, early clinical trials continue for an experimental drug abiraterone on tumors in men who haven’t responded to other therapies. More research is underway and it will be some time before the results are completely known.

* Source: http://www.annals.org/cgi/content/full/149/3/185

About the prostate gland

A small gland the size of a walnut, the prostate is exclusive to men. Located underneath the bladder and in front of the rectum the prostate is part of the body’s semen making process. It’s triggered by testosterone, a male hormone, which can influence the behavior of the prostate gland and prostate cancer. Nerves to the penis important in producing and maintaining an erection run very close to the prostate. And the urethra runs through the prostate. If the prostate enlarges, it can block the flow of urine from the bladder making it difficult for a man to urinate.

About prostate cancer

There are different types of tumors and not all are cancerous. Those that cannot spread or threaten a life are benign. Those that invade surrounding tissue and even spread throughout the body are malignant tumors. Most prostate cancer is very slow growing and will never endanger or affect quality of life. However, sometimes these cells grow quickly, spread to nearby tissue and lymph nodes. If prostate cancer has spread to the patient’s lymph nodes when it is diagnosed, it means that there is higher chance that it has spread to other areas of the body.

Risk factors

Researchers at University of Pennsylvania’s Abramson Cancer Center believe every man over the age of 45 is at risk for prostate cancer. The American Cancer Society recommends screening of men 50 and older. Age is most often a factor as 70% of men diagnosed with prostate cancer are over the age of 65. It is 2nd in occurrence to skin cancer in the US. One man in six will develop prostate cancer and one in 35 will die from it. In between are men whose quality of life will be changed by it.

Risk factors include age, age as incidence of prostate cancer rises quickly after the age of 60, and the majority of men will have some form of prostate cancer after the age of 80. It is said that that older men (over the age of 80) die with prostate cancer not from prostate cancer. It means that many men have developed the slow growing microscopic form of prostate cancer but is not life threatening. The controversy about this difficult form of cancer is that the rarer form can grow quickly even in older patients. Current screening is not perfect in discerning which type of cancer is developing.

Another risk factor is ethnicity. Men of African-American decent and of Latin descent tend to have a higher risk of developing prostate cancer. Men of Asian or Native American descent have a lower risk. Caucasian men fall in the middle. This risk factor is not well understood. While genetics may be a factor, there is some evidence that diet may be a factor. Some studies indicate that a diet high in animal fat may raise a man’s risk of developing prostate cancer. Conversely a diet low in vegetables may also raise risk.

Family history is the third risk factor known today. A father or brother with prostate cancer increases a man’s risk of developing prostate cancer. With a family history of prostate cancer developed at a younger age the risk increases even more. Certain mutations in genes may have an increase in prostate cancer risk as well as men with high levels of testosterone.

Prevention             Return to top

Because so many men will develop prostate cancer there is a lot of interest in trying to prevent it with drug therapy, and the consumption of certain foods or nutrients. Little is known about this complex disease and much research is underway. At this time prevention includes the patient taking control over his own health. That includes a low fat diet that is rich in fruits and vegetables. Although certain foods and nutrients are being researched more data is needed. Currently, there are studies looking at selenium, lycopene, vitamin A and other retinoids, vitamin D, vitamin E, and soy for prostate cancer prevention.

Drugs like Flutamide and Finasteride can decrease the levels of testosterone in the prostate to attempt to stop prostate cancer from forming and growing. They are currently under investigation for prostate cancer prevention. Drugs that decrease total body testosterone have many undesirable side effects and are not considered a good choice for prostate cancer prevention.

Screening

Screening for prostate cancer is a highly controversial issue. There is no good data showing that screening for prostate cancer reduces deaths from prostate cancer. There are currently very large trials on-going to see which populations of men will benefit most.

The American Cancer Society, the American Urological Society, and many medical communities recommend screening annually for men 50 and over. Two methods are used: a digital rectal exam (DRE) and a prostate specific antigen (PSA) blood test. The digital rectal exam is done in the primary care physician's office. Because the prostate is so close to the rectum, a doctor can feel it by inserting a gloved, lubricated finger into the anus. Lumps, asymmetries, or an enlarged prostate can be detected this way though some small cancers can be missed. A PSA looks for a protein that the prostate makes. Normal prostate tissue makes a little bit of PSA, but prostate cancer usually makes much more. An elevated PSA may suggest that a malignant tumor is present. False positive tests exist. For that reason doctors really on the combination of a PSA blood test and a DRE. If there is doubt, the physician may recommend a sample of prostate tissue from a biopsy be taken for further study. Some doctors don't think screening for prostate cancer is worth doing. Downsides include an extensive workup and treatment for a disease that never would have shortened a life. The treatment options for prostate cancer each have the potential for side effects. Another argument against prostate cancer screening is that it has never been proven to save lives in studies of large populations. Many doctors think that newer treatments for early stage prostate cancers will make the screening process necessary by all standards.

Symptoms             Return to top

Most early prostate cancers are detected with PSA tests or digital rectal exams before they cause any symptoms. More advanced prostate cancers can cause a variety of symptoms including:

  • trouble starting urination
  • urinating much more frequently than usual
  • the feeling that you can't release all of your urine
  • pain on urination or ejaculation
  • blood in your urine or semen
  • impotence
  • bone pain

All of the symptoms listed here can be caused by a number of things besides prostate cancer. If the patient experiences any of these symptoms further screening should be discussed.

Diagnosis

If the patient experience symptoms, the doctor will do a digital rectal exam and a PSA blood test. If either of those two tests is abnormal, the doctor will probably recommend a biopsy. Once the tissue is removed, a pathologist will review the specimen. The pathologist can tell if it is cancer or not; and if it is cancerous, then the pathologist will characterize it by what type of prostate cancer it is and how abnormal it looks (known as the grade).

Treatment             Return to top

There are many different ways to treat prostate cancer, and consulting multiple types of doctors before making a final decision. Physicians are not always in agreement as to the way to proceed because there haven't been enough large trials that compare the different treatment modalities. A second opinion is standard. Talking with both urologists and radiation oncologists to discuss the benefits and risks of surgery, hormonal therapy, and radiation treatment including brachytherapy, chemotherapy, and cryosurgery is suggested. “Watchful Waiting” is the choice of some patients and their physician in the hopes it will be a slow growing cancer. Once a patient has been treated for prostate cancer follow up visits are done on a regular schedule, often at first then less often as the patient is free of the disease.

The following information is provided for a better understanding of the disease and does not replace the dialogue men should have with their physician regarding screening and treatment for prostate cancer.

Adapted from OncoLink, University of Pennsylvania

 

Healthcare Professional Information About Prostate Cancer

Prostate Info

About the prostate gland

About prostate cancer

Risk factors

Prevention

Screening

Symptoms

Diagnosis

Treatment

 

link